journal
MENU ▼
Read by QxMD icon Read
search

Regenerative Medicine

journal
https://www.readbyqxmd.com/read/27925870/hydrogen-sulfide-enhances-pancreatic-%C3%AE-cell-differentiation-from-human-tooth-under-normal-and-glucotoxic-conditions
#1
Ioan Valentin Matei, Hisataka Ii, Ken Yaegaki
AIM: Glucotoxicity obstructs pancreatic differentiation from adult stem cells. The aim was to develop a novel protocol for differentiation of dental pulp stem cells (DPSCs) into pancreatic β cells and determine the effect of H2S on glucotoxicity. MATERIALS & METHODS: DPSCs were differentiated with media containing 5.5 or 25.0 mM glucose, exposed to 1 ng/ml H2S. Glucotoxicity, expression of β-cell markers, INS, PDX1 and GLUT2, and PI3K/AKT pathway were assessed...
December 7, 2016: Regenerative Medicine
https://www.readbyqxmd.com/read/27977331/cell-therapies-administered-in-the-chronic-phase-after-stroke-a-meta-analysis-examining-safety-and-efficacy
#2
David J Unsworth, Jane L Mathias, Diana S Dorstyn
AIM: To assess the safety and efficacy of cell therapies for chronic stroke. METHODOLOGY: Five databases were searched for treatments administered >90 days post-stroke. Reporting quality, adherence to research guidelines, treatment safety (risk ratios/pooled incidence rates) and neurological/functional efficacy (Hedge's g) were all evaluated. RESULTS: Twenty-three studies examined 17 treatments. Reporting quality scores were medium to high, but adherence to recommended guidelines was lower...
January 2017: Regenerative Medicine
https://www.readbyqxmd.com/read/27976982/patent-eligibility-of-stem-cells-in-europe-where-do-we-stand-after-8-years-of-case-law
#3
Ulrich Storz, Timo Faltus
Since 2006, some of the highest ranking European Courts have issued decisions related to the patent eligibility of human embryonic stem cells. The question of patent eligibility of human embryonic stem cells remains, however, still erratic, at least in some aspects. This article will give a short comprehensive overview of the case history, and discuss questions still unsolved.
January 2017: Regenerative Medicine
https://www.readbyqxmd.com/read/27976977/generation-of-endoderm-lineages-from-pluripotent-stem-cells
#4
Xie Luo, Han Wang, Jake Leighton, Mara O'Sullivan, Pei Wang
Definitive endoderm is the cellular precursor to respiratory- and digestive-related organs such as lungs, stomach, liver, pancreas and intestine. Endodermal lineage cells derived from pluripotent stem cells (PSCs) in vitro are a potentially unlimited resource for regenerative medicine. These cells are useful tools for studying the physiology, pathogenesis and medical therapies involving these tissues, and great progress has been achieved in PSCs differentiation protocols. In this review, we will focus on the most common and/or advanced differentiation strategies currently used in generating endodermal lineage cells from PSCs...
January 2017: Regenerative Medicine
https://www.readbyqxmd.com/read/27976967/the-ethics-of-withdrawal-the-case-of-follow-up-from-first-in-human-clinical-trials
#5
Kristina Hug, Mats Johansson
This paper aims to analyze whether patients should be allowed to veto research-related use of medical data collected during routine follow-ups after their withdrawal from first-in-human clinical trials. Forms of withdrawal are identified and it is argued that the right to withdraw might be limited to some of these. The paper concludes that if veto right is denied, then: the research participant should be informed about the potential use of his/her follow-up data in case of his/her withdrawal and consent to it; follow-up should not be initiated for research purposes; compulsory use of follow-up data should imply the use of data anyway collected, requiring no additional effort from the patient; and before deciding about the veto right, investigation of concerned patients' value preferences is needed...
January 2017: Regenerative Medicine
https://www.readbyqxmd.com/read/27925505/prioritizing-studies-on-regeneration-in-nontraditional-model-organisms
#6
Benjamin L King, Viravuth P Yin
No abstract text is available yet for this article.
January 2017: Regenerative Medicine
https://www.readbyqxmd.com/read/27900887/toward-modeling-the-human-nervous-system-in-a-dish-recent-progress-and-outstanding-challenges
#7
Barbora Vagaska, Patrizia Ferretti
Studying the cellular and molecular bases governing development, and normal and abnormal functions of the human CNS is hampered by its complexity and the very limited possibility of experimentally manipulating it in vivo. Development of 3D, tissue-like culture systems offers much promise for boosting our understanding of human neural development, birth defects, neurodegenerative diseases and neural injury, and for providing platforms that will more accurately predict efficacy of putative therapeutic compounds and assess responses to potentially neurotoxic agents...
January 2017: Regenerative Medicine
https://www.readbyqxmd.com/read/27900882/latest-developments-in-the-field-of-stem-cell-research-and-regenerative-medicine-compiled-from-publicly-available-information-and-press-releases-from-nonacademic-institutions-1-30-september-2016
#8
https://www.readbyqxmd.com/read/27900881/our-panel-of-experts-highlight-the-most-important-research-articles-across-the-spectrum-of-topics-relevant-to-the-field-of-regenerative-medicine
#9
Amber Kerstetter-Fogle
No abstract text is available yet for this article.
January 2017: Regenerative Medicine
https://www.readbyqxmd.com/read/27900877/mesenchymal-stem-cells-a-promising-tool-for-targeted-gene-therapy-of-endometriosis
#10
Aghila Rani Koippallil Gopalakrishnan, Uday Kishore, Taruna Madan
Endometriosis is a leading, benign gynecological disorder around the world. Last few years have witnessed tremendous growth in the field of endometriosis and endometrial stem-cell research. Despite advancements in the biology and pathology of endometriosis, disease recurrence is still an enigma. Gene therapy holds promise in treating many pathologic conditions including endometriosis. Mesenchymal stem cells (MSCs) serve as ideal candidates for regenerative medicine and cell-based therapies. Owing to their specificity to the endometrium, residing endometrial MSC populations could be utilized as ideal candidates for targeting endometrial disorders...
January 2017: Regenerative Medicine
https://www.readbyqxmd.com/read/27900874/human-pluripotent-stem-cells-in-modeling-human-disorders-the-case-of-fragile-x-syndrome
#11
Dan Vershkov, Nissim Benvenisty
Human pluripotent stem cells (PSCs) generated from affected blastocysts or from patient-derived somatic cells are an emerging platform for disease modeling and drug discovery. Fragile X syndrome (FXS), the leading cause of inherited intellectual disability, was one of the first disorders modeled in both embryonic stem cells and induced PCSs and can serve as an exemplary case for the utilization of human PSCs in the study of human diseases. Over the past decade, FXS-PSCs have been used to address the fundamental questions regarding the pathophysiology of FXS...
January 2017: Regenerative Medicine
https://www.readbyqxmd.com/read/27911242/regenerative-medicine-the-last-10-years
#12
Robert Lanza
No abstract text is available yet for this article.
December 2016: Regenerative Medicine
https://www.readbyqxmd.com/read/27908225/regen-med-california-institute-for-regenerative-medicine-profile-cirm-2-0
#13
Kevin McCormack
The California Institute for Regenerative Medicine was created by the voters of California in 2004 to accelerate stem cell treatments to patients with unmet medical needs. By the end of its first 10 years, the agency was funding ten projects in clinical trials, including work in heart disease and cancer, HIV/AIDS and Type 1 diabetes. The goal now is to significantly increase that number, adding another 50 clinical trial projects funded by California Institute for Regenerative Medicine over the next 5 years...
December 2016: Regenerative Medicine
https://www.readbyqxmd.com/read/27908220/pluripotent-stem-cells-the-last-10-years
#14
Erin A Kimbrel, Robert Lanza
Pluripotent stem cells (PSCs) can differentiate into virtually any cell type in the body, making them attractive for both regenerative medicine and drug discovery. Over the past 10 years, technological advances and innovative platforms have yielded first-in-man PSC-based clinical trials and opened up new approaches for disease modeling and drug development. Induced PSCs have become the foremost alternative to embryonic stem cells and accelerated the development of disease-in-a-dish models. Over the years and with each new discovery, PSCs have proven to be extremely versatile...
December 2016: Regenerative Medicine
https://www.readbyqxmd.com/read/27905261/beneath-the-sword-of-damocles-regenerative-medicine-and-the-shadow-of-immunogenicity
#15
Paul J Fairchild, Christopher Horton, Priyoshi Lahiri, Kumaran Shanmugarajah, Timothy J Davies
Few topics in regenerative medicine have inspired such impassioned debate as the immunogenicity of cell types and tissues differentiated from pluripotent stem cells. While early predictions suggested that tissues derived from allogeneic sources may evade immune surveillance altogether, the pendulum has since swung to the opposite extreme, with reports that the ectopic expression of a few developmental antigens may prompt rejection, even of tissues differentiated from autologous cell lines. Here we review the evidence on which these contradictory claims are based in order to reach an objective assessment of the likely magnitude of the immunological challenges ahead...
December 2016: Regenerative Medicine
https://www.readbyqxmd.com/read/27905260/ccrm-cultivating-a-culture-of-cooperation-to-advance-the-global-regenerative-medicine-industry
#16
Alanna Evans, Stacey Johnson
Launched in June 2011, CCRM is a unique, Canadian, not-for-profit group that is solely focused on developing and commercializing regenerative medicine, cell and gene therapy technologies. Its mission is to generate sustainable health and economic benefits through global collaborations, and its vision is to be the preferred destination for the best people and companies, technologies, clinical trials and investments in cell and gene therapies, and regenerative medicine.
December 2016: Regenerative Medicine
https://www.readbyqxmd.com/read/27905259/regenerative-pharmacology-recent-developments-and-future-perspectives
#17
James Koudy Williams, Karl-Erik Andersson
This review focuses on the current status of research that utilizes the application of pharmacological sciences to accelerate, optimize and characterize the development, maturation and function of bioengineered and regenerating tissues. These regenerative pharmacologic approaches have been applied to diseases of the urogenital tract, the heart, the brain, the musculoskeletal system and diabetes. Approaches have included the use of growth factors (such as VEGF and chemokines (stromal-derived factor - CXCL12) to mobilize cell to the sights of tissue loss or damage...
December 2016: Regenerative Medicine
https://www.readbyqxmd.com/read/27905217/to-crispr-and-beyond-the-evolution-of-genome-editing-in-stem-cells
#18
Kuang-Yui Chen, Paul S Knoepfler
The goal of editing the genomes of stem cells to generate model organisms and cell lines for genetic and biological studies has been pursued for decades. There is also exciting potential for future clinical impact in humans. While recent, rapid advances in targeted nuclease technologies have led to unprecedented accessibility and ease of gene editing, biology has benefited from past directed gene modification via homologous recombination, gene traps and other transgenic methodologies. Here we review the history of genome editing in stem cells (including via zinc finger nucleases, transcription activator-like effector nucleases and CRISPR-Cas9), discuss recent developments leading to the implementation of stem cell gene therapies in clinical trials and consider the prospects for future advances in this rapidly evolving field...
December 2016: Regenerative Medicine
https://www.readbyqxmd.com/read/27885917/latest-developments-in-the-field-of-stem-cell-research-and-regenerative-medicine-compiled-from-publicly-available-information-and-press-releases-from-nonacademic-institutions-1-july-31-august-2016
#19
https://www.readbyqxmd.com/read/27885902/regenerative-medicine-looking-backward-10-years-further-on
#20
Paul Kemp
The last decade has seen considerable changes in the Regenerative Medicine industry, but unfortunately the hope for numerous treatments that 'replace or regenerate human cells, tissues or organs to restore or establish normal function' has not yet emerged. In contrast to this, there have been major advances in the field of cellular immunotherapy though some do not consider these to be Regenerative Medicines. Regulatory changes have in some cases improved the route to a marketing license but they have not been matched by clarification of the complex, national reimbursement processes for cell-based treatments and this has adversely affected a number of leading Regenerative Medicine Companies...
December 2016: Regenerative Medicine
journal
journal
41393
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"